Lilly’s Retevmo meets primary endpoint in Phase 3 NSCLC study
In the trial, the RET kinase inhibitor showed a clinically meaningful and statistically significant improvement in progression-free survival…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
07 Aug 23
In the trial, the RET kinase inhibitor showed a clinically meaningful and statistically significant improvement in progression-free survival…
07 Aug 23
Leveraging its extensive knowledge and capabilities in cell engineering, ultra-high-throughput multiplexed screening, protein characterisation, and process optimisation, Ginkgo…
07 Aug 23
BIMERVAX: A booster dose of bivalent recombinant protein vaccine provides immunisation in people over 16 years of age
07 Aug 23
Company aims to reach goal by using less plastic, more recycled content, and alternatives to plastic
07 Aug 23
The report showcases key sustainability achievements from 2022, highlighting progress and setting the stage for future action
07 Aug 23
TreeHouse Foods, Inc. (NYSE: THS), a leading private label food and beverage manufacturer in North America, today announced…
07 Aug 23
SFD’s development loan will help to provide an integrated medical facility offering secondary medical care to Saint Lucia’s…
07 Aug 23
The Big Build brought together 100 participants from 17 conservation and science partners across government, NGO, business sectors, and…
04 Aug 23
In exchange for the exclusive global right to the TMPRSS6 siRNA programme, Alnylam will receive a $17.5m upfront…
04 Aug 23
ERVEBO is a live recombinant viral vaccine that includes a vesicular stomatitis virus backbone deleted for the VSV…